You are in: eMedicine Specialties > Infectious Diseases > MEDICAL TOPICS SarcosporidiosisArticle Last Updated: Feb 15, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Raphael J Kiel, MD, Associate Professor of Medicine, Wayne State University School of Medicine; Associate Program Director, Head of Infectious Disease Section, Department of Internal Medicine, Oakwood Hospital Raphael J Kiel is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Geriatrics Society, American Medical Association, and American Medical Informatics Association Editors: Kenneth C Earhart, MD, FACP, Deputy Head, Disease Surveillance Program, United States Naval Medical Research Unit #3; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Joseph F John Jr, MD, FACP, FIDSA, FSHEA, Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina; Associate Chief of Staff for Education, Ralph H Johnson Veteran's Administration Medical Center; Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital; Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital Author and Editor Disclosure Synonyms and related keywords: sarcosporidiosis, sarcocystosis, Sarcocystis species, Sarcocystidae, eosinophilic myositis syndrome, oocysts, sporocysts, intracellular protozoan parasites, myositis, enteritis, trypanosomiasis, Trypanosoma cruzi infection INTRODUCTIONBackgroundSarcosporidiosis (Sarcocystis infection) is caused by an intracellular protozoan parasite that predominantly affects animals. It can rarely be found in human skeletal and cardiac muscle when humans are the intermediate or accidental host. Humans can also serve as the definitive host for this parasite after ingesting the cysts in raw or undercooked beef or pork. After invasion of the GI tract, the infective sporozoites replicate and are subsequently eliminated in the stool. These oocysts are ingested by an intermediate host (eg, usually cow or pig) to complete the life cycle. PathophysiologySarcosporidiosis in humans has 2 distinct forms. In the first form, ingestion of water or food contaminated with sporocysts from the feces of a carnivore (eg, dog, wolf) is followed by sporocyst penetration of the intestinal wall. Proliferation in vascular endothelium and subsequent hematogenous dissemination leads to invasion of skeletal and cardiac muscle. These cysts subsequently disintegrate with accompanying vasculitis and fibrosis of the tissue (myositis). The second form of sarcosporidiosis in man occurs after ingestion of meat contaminated by infective oocysts. The oocysts undergo sexual reproduction and maturation in the intestinal tract. Infective oocysts are shed into the stool (enteritis). A systemic phase and a subsequent tissue phase do not occur in this form of the infection. FrequencyUnited StatesSarcosporidiosis has worldwide distribution. In the United States, more than 60 cases of muscle involvement by Sarcocystis species have been described, mostly in collections of case reports of 5-10 cases. Since this finding is often incidental, many more undetected cases probably exist. The definitive form of sarcosporidiosis causes a self-limited nonspecific enteritis and is often not suspected clinically. InternationalMost cases of human sarcosporidiosis occur in Southeast Asia. The incidence of intestinal Sarcocystis infection in Thai laborers was measured at 23%. A study of autopsy specimens of patients in Southeast Asia showed a prevalence rate of 21% in 100 consecutive patients evaluated. The seroprevalence of sarcosporidiosis in Malaysia was estimated at 19.8%. Mortality/MorbidityAlthough sarcosporidiosis can involve the heart, no deaths specifically related to its myocardial involvement have been documented. Painful muscle swellings, fever, and weakness can occur with skeletal muscle involvement. Sarcosporidiosis has not been described as causing a chronic diarrhea or malabsorptive state. RaceThe condition has no known race predilection, but most described cases have been from Southeast Asia. SexThe condition has no known sex predilection. AgeThe condition has no known age predilection; however, because muscle involvement clinically occurs after cyst deterioration, adults are more likely to present with skeletal muscle involvement than are children. CLINICALHistoryPatient history in the myositic form of sarcosporidiosis includes painful muscle swellings accompanied by erythema, muscle tenderness, generalized muscle weakness, and fever. Bronchospasm can also occur. Cardiac involvement is asymptomatic, but sarcosporidiosis has been known to cause second-degree atrioventricular block in sheep. Within a day after ingestion of contaminated beef or pork, subjects who develop the enteritis form of this infection have diaphoresis, chills, fever, vomiting, and diarrhea. Physical
CausesThe following persons have an increased risk of Sarcocystis infection:
DIFFERENTIALSCryptosporidiosis Cysticercosis Giardiasis Isosporiasis Toxoplasmosis
|
| Drug Name | Prednisone (Deltasone, Orasone, Meticorten) |
|---|---|
| Description | Used to treat a variety of diseases, including connective tissue disease and inflammatory and allergic disorders. In addition, it is used for adrenocortical insufficiency, neoplastic diseases, and organ transplantation. |
| Adult Dose | 20-40 mg/d PO for 7-10 d |
| Pediatric Dose | 15-30 mg/d PO adjusted to body weight for 7-10 d |
| Contraindications | Documented hypersensitivity; viral infection, peptic ulcer disease, hepatic dysfunction, connective tissue infections, and fungal or tubercular skin infections; GI disease |
| Interactions | Coadministration with estrogens may decrease clearance; concurrent use with digoxin, may cause digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur with glucocorticoid use |
Therapy must be comprehensive and cover all likely pathogens in the context of this clinical setting.
| Drug Name | Sulfamethoxazole (SMZ) and trimethoprim (TMP) (Bactrim, Bactrim DS, Septra, Sept |
|---|---|
| Description | Used to treat a variety of infectious diseases, including urinary tract infections (not due to pseudomonads), Pneumocystis carinii infection, and staphylococcal infections. |
| Adult Dose | 160 mg TMP/800 mg SMZ PO q12h for 10-14 d |
| Pediatric Dose | <2 months: Do not administer >2 months: 15-20 mg/kg/d (based on TMP) PO tid/qid for 14 d |
| Contraindications | Documented hypersensitivity; megaloblastic anemia due to folate deficiency |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly patients; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow suppression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Discontinue at first appearance of skin rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow suppression (if signs occur, administer 5-15 mg/d leucovorin); caution in folate deficiency (eg, patients with chronic alcoholism, elderly patients, those receiving anticonvulsant therapy, or those with malabsorption syndrome); hemolysis may occur in patients with G-6-PD deficiency; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); administer fluids to prevent crystalluria and stone formation |
| Drug Name | Metronidazole (Flagyl) |
|---|---|
| Description | Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Used in combination with other antimicrobial agents (except for Clostridium difficile enterocolitis). |
| Adult Dose | Loading dose: 15 mg/kg IV or 1 g for 70-kg adult IV over 1 h Maintenance dose (6 h following loading dose): 7.5 mg/kg or 500 mg for 70-kg adult IV infusion over 1 h q6-8h; not to exceed 4 g/d |
| Pediatric Dose | Administer as in adults using body weight |
| Contraindications | Documented hypersensitivity |
| Interactions | May increase toxicity of anticoagulants, lithium, and phenytoin; cimetidine may increase toxicity of metronidazole; disulfiram reaction may occur with orally ingested ethanol |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy |
Article Last Updated: Feb 15, 2006